In­novent bets $250M+ on Union's PDE4 in­hibitor ahead of a PhII read­out

A year af­ter pluck­ing oris­mi­last from Leo Phar­ma­ceu­ti­cals’ pipeline — and with­out pub­lish­ing any mid-stage da­ta — Union Ther­a­peu­tics is al­ready mak­ing a pret­ty pen­ny on the oral PDE4 in­hibitor.

In­novent Bi­o­log­ics is shelling out $20 mil­lion up­front for de­vel­op­ment and com­mer­cial­iza­tion rights to Union’s “Phase III-ready” oral for­mu­la­tion of oris­mi­last in Chi­na, the com­pa­nies said ear­ly Tues­day morn­ing. Hop­ing to one-up Am­gen’s block­buster PDE4 in­hibitor Ote­zla in terms of po­ten­cy, Union’s been push­ing the can­di­date through Phase II tri­als in skin con­di­tions like pso­ri­a­sis, atopic der­mati­tis and hidradeni­tis sup­pu­ra­ti­va.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER